Lista de obras - Carmen Balaña - Dominio Público Uruguay

2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary

artículo científico publicado en 2018

A Comparison of RNA-Seq Results from Paired Formalin-Fixed Paraffin-Embedded and Fresh-Frozen Glioblastoma Tissue Samples

artículo científico publicado en 2017

A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate.

artículo científico publicado en 2006

A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma

scientific article published on 23 February 2019

A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma

artículo científico publicado en 2014

A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site.

artículo científico publicado en 2003

A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.

artículo científico publicado en 2015

ACTR-48. AN APPRAISAL OF THE IMPACT ON SURVIVAL OF NEOADJUVANT TREATMENTS DELAYING RADIOTHERAPY IN ‘ONLY-BIOPSIED GLIOBLASTOMA’ TRIALS CONDUCTED BY THE GEINO GROUP COMPARED TO PATIENTS TREATED WITH THE STUPP’S REGIME. EXPERIENCE OF THE GEINO AND THE

ATCT-05OBJECTIVE RESPONSE (OR) TO NEOADJUVANT TREATMENT IN GLIOBLASTOMA AND ITS IMPACT ON OVERALL SURVIVAL (OS). A META-ANALYSIS OF NEOADJUVANT TRIALS OF THE SPANISH GROUP FOR RESEARCH IN NEUROONCOLOGY (GEINO).

artículo científico publicado en 2015

Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?

artículo científico publicado en 2011

Assessment of neurocognitive decline in cancer patients, except brain cancer, under long-term treatment with bevacizumab

scientific article published on 29 May 2019

Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.

artículo científico publicado en 2016

Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).

artículo científico publicado en 2012

Bevacizumab rechallenge in glioblastoma patients with initial response to bevacizumab who later progress off therapy

scientific article published on 18 May 2018

Clinical course of high-grade glioma patients with a "biopsy-only" surgical approach: a need for individualised treatment.

artículo científico publicado en 2007

Correction to: SEOM clinical guidelines for anaplastic gliomas (2017)

artículo científico publicado en 2018

CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas

artículo científico publicado en 2004

Dacomitinib: an investigational drug for the treatment of glioblastoma

artículo científico publicado en 2018

Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients.

artículo científico publicado en 2018

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.

artículo científico publicado en 2014

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

scientific article published on 08 December 2020

ET-12PHASE II STUDY OF ONARTUZUMAB PLUS BEVACIZUMAB VERSUS PLACEBO PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA.

artículo científico publicado en 2014

Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma

artículo científico publicado en 2017

Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry

artículo científico publicado en 2013

Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors ⬇️

artículo científico publicado el 7 de marzo de 2013

Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program

artículo científico publicado en 2019

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis

artículo científico publicado en 2016

Epirubicin plus a calmodulin inhibitor (trifluoperazine) activity in advanced pancreatic adenocarcinoma. T.T.D. Cooperative Spanish Group

artículo científico publicado en 1994

Erratum to: Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry.

artículo científico publicado en 2014

European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.

artículo científico publicado en 2017

Evidence-based management of adult patients with diffuse glioma - Authors' reply

artículo científico publicado en 2017

Evolution of care for patients with relapsed glioblastoma.

artículo científico publicado en 2011

Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.

artículo científico publicado en 2018

Extended-schedule dose-dense temozolomide in refractory gliomas

artículo científico publicado en 2009

Federated learning enables big data for rare cancer boundary detection

Genotyping low-grade gliomas among Hispanics

scientific article published on 28 January 2016

Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients

artículo científico publicado en 2016

IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.

artículo científico publicado en 2017

Induction chemotherapy in the treatment of head and neck cancer in advanced stages

artículo científico publicado en 1992

Is a pretreatment radiological staging system feasible for suggesting the optimal extent of resection and predicting prognosis in glioblastoma? An observational study

artículo científico publicado en 2017

Macrovascular Networks on Contrast-Enhanced Magnetic Resonance Imaging Improves Survival Prediction in Newly Diagnosed Glioblastoma

artículo científico publicado en 2019

Medulloblastoma in young adults. Must we give adjuvant chemotherapy?

artículo científico publicado en 2007

Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation.

artículo científico publicado en 2014

P04.03 Extent of surgery improves the overall survival independently of imaging characteristics in newly diagnosed glioblastoma.

artículo científico publicado en 2017

P17.04RANO CRITERIA APPLIED TO A PHASE II RANDOMIZED, MULTICENTER TRIAL COMPARING TEMOZOLOMIDE (TMZ) VS TMZ-PLUS-BEVACIZUMAB (BEV) BEFORE STANDARD TREATMENT IN UNRESECTABLE GLIOBLASTOMA (GBM) PATIENTS (P).GENOM 009 STUDY BY THE GEINO GROUP.

artículo científico publicado en 2014

Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study.

artículo científico publicado en 2006

Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification

artículo científico publicado en 2017

Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma.

artículo científico publicado en 2015

Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors.

artículo científico publicado en 2012

Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab†

scientific article published on 09 December 2016

Pseudoprogression as an adverse event of glioblastoma therapy

artículo científico publicado en 2017

Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients

artículo científico publicado en 2019

Radiation and concomitant chemotherapy for patients with glioblastoma multiforme

artículo científico publicado en 2014

Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study.

artículo científico publicado en 2016

Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study

artículo científico publicado en 2005

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA

artículo científico publicado en 2016

Results of a multicenter survey showing interindividual variability among neurosurgeons when deciding on the radicality of surgical resection in glioblastoma highlight the need for more objective guidelines

artículo científico publicado en 2016

Rheumatoid arthritis and multiple neoplasms

artículo científico publicado el 28 de septiembre de 1991

SEOM clinical guidelines for anaplastic gliomas (2017).

artículo científico publicado en 2017

SEOM guideline for the treatment of malignant glioma

artículo científico publicado en 2012

SURG-01IS UNRESECTED GLIOBLASTOMA TRULY UNRESECTABLE? AN ANALYSIS OF BASAL MRI'S OF PATIENTS WITH UNRESECTED GLIOBLASTOMA INCLUDED IN THE GENOM009 TRIAL AND THE VARIABILITY OF SURGICAL APPROACHES.

artículo científico publicado en 2015

Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS).

artículo científico publicado en 2004

Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).

artículo científico publicado en 2004

Serum DNA as a tool for cancer patient management

artículo científico publicado en 2003

Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain.

artículo científico publicado en 2013

Stem Cells in Brain Tumorigenesis and their Impact on Therapy ⬇️

artículo científico publicado el 1 de diciembre de 2011

Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a phase II study.

artículo científico publicado en 2014

Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib

scientific article published on 20 June 2019

Translational research in glioblastoma multiforme: molecular criteria for patient selection.

artículo científico publicado en 2008

Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients

artículo científico publicado en 2011

Update on the diagnosis of cancer of unknown primary (CUP) origin

artículo científico publicado en 2011

Use of 201Tl SPECT imaging to assess the response to therapy in patients with high grade gliomas

artículo científico publicado en 2002

Validation of the new Graded Prognostic Assessment scale for brain metastases: a multicenter prospective study.

artículo científico publicado en 2011

[2018 Consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary]

scientific article published on 10 October 2018

Lista de obras de Carmen Balaña

2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary

A Comparison of RNA-Seq Results from Paired Formalin-Fixed Paraffin-Embedded and Fresh-Frozen Glioblastoma Tissue Samples

A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate.

A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma

A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma

A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site.

A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.

ACTR-48. AN APPRAISAL OF THE IMPACT ON SURVIVAL OF NEOADJUVANT TREATMENTS DELAYING RADIOTHERAPY IN ‘ONLY-BIOPSIED GLIOBLASTOMA’ TRIALS CONDUCTED BY THE GEINO GROUP COMPARED TO PATIENTS TREATED WITH THE STUPP’S REGIME. EXPERIENCE OF THE GEINO AND THE

ATCT-05OBJECTIVE RESPONSE (OR) TO NEOADJUVANT TREATMENT IN GLIOBLASTOMA AND ITS IMPACT ON OVERALL SURVIVAL (OS). A META-ANALYSIS OF NEOADJUVANT TRIALS OF THE SPANISH GROUP FOR RESEARCH IN NEUROONCOLOGY (GEINO).

Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?

Assessment of neurocognitive decline in cancer patients, except brain cancer, under long-term treatment with bevacizumab

Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.

Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).

Bevacizumab rechallenge in glioblastoma patients with initial response to bevacizumab who later progress off therapy

Clinical course of high-grade glioma patients with a "biopsy-only" surgical approach: a need for individualised treatment.

Correction to: SEOM clinical guidelines for anaplastic gliomas (2017)

CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas

Dacomitinib: an investigational drug for the treatment of glioblastoma

Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients.

EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

ET-12PHASE II STUDY OF ONARTUZUMAB PLUS BEVACIZUMAB VERSUS PLACEBO PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA.

Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma

Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry

Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors ⬇️

Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis

Epirubicin plus a calmodulin inhibitor (trifluoperazine) activity in advanced pancreatic adenocarcinoma. T.T.D. Cooperative Spanish Group

Erratum to: Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry.

European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.

Evidence-based management of adult patients with diffuse glioma - Authors' reply

Evolution of care for patients with relapsed glioblastoma.

Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial.

Extended-schedule dose-dense temozolomide in refractory gliomas

Federated learning enables big data for rare cancer boundary detection

Genotyping low-grade gliomas among Hispanics

Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients

IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.

Induction chemotherapy in the treatment of head and neck cancer in advanced stages

Is a pretreatment radiological staging system feasible for suggesting the optimal extent of resection and predicting prognosis in glioblastoma? An observational study

Macrovascular Networks on Contrast-Enhanced Magnetic Resonance Imaging Improves Survival Prediction in Newly Diagnosed Glioblastoma

Medulloblastoma in young adults. Must we give adjuvant chemotherapy?

Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation.

P04.03 Extent of surgery improves the overall survival independently of imaging characteristics in newly diagnosed glioblastoma.

P17.04RANO CRITERIA APPLIED TO A PHASE II RANDOMIZED, MULTICENTER TRIAL COMPARING TEMOZOLOMIDE (TMZ) VS TMZ-PLUS-BEVACIZUMAB (BEV) BEFORE STANDARD TREATMENT IN UNRESECTABLE GLIOBLASTOMA (GBM) PATIENTS (P).GENOM 009 STUDY BY THE GEINO GROUP.

Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study.

Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification

Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma.

Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors.

Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab†

Pseudoprogression as an adverse event of glioblastoma therapy

Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients

Radiation and concomitant chemotherapy for patients with glioblastoma multiforme

Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study.

Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA

Results of a multicenter survey showing interindividual variability among neurosurgeons when deciding on the radicality of surgical resection in glioblastoma highlight the need for more objective guidelines

Rheumatoid arthritis and multiple neoplasms

SEOM clinical guidelines for anaplastic gliomas (2017).

SEOM guideline for the treatment of malignant glioma

SURG-01IS UNRESECTED GLIOBLASTOMA TRULY UNRESECTABLE? AN ANALYSIS OF BASAL MRI'S OF PATIENTS WITH UNRESECTED GLIOBLASTOMA INCLUDED IN THE GENOM009 TRIAL AND THE VARIABILITY OF SURGICAL APPROACHES.

Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS).

Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).

Serum DNA as a tool for cancer patient management

Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain.

Stem Cells in Brain Tumorigenesis and their Impact on Therapy ⬇️

Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a phase II study.

Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib

Translational research in glioblastoma multiforme: molecular criteria for patient selection.

Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients

Update on the diagnosis of cancer of unknown primary (CUP) origin

Use of 201Tl SPECT imaging to assess the response to therapy in patients with high grade gliomas

Validation of the new Graded Prognostic Assessment scale for brain metastases: a multicenter prospective study.

[2018 Consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary]